State of New Jersey Common Pension Fund D Raises Position in Illumina, Inc. (NASDAQ:ILMN)

State of New Jersey Common Pension Fund D grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 93,042 shares of the life sciences company’s stock after purchasing an additional 2,237 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.06% of Illumina worth $12,955,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Illumina during the 3rd quarter worth $30,000. VisionPoint Advisory Group LLC increased its holdings in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in Illumina in the 4th quarter valued at $37,000. Gradient Investments LLC increased its holdings in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. increased its holdings in Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on ILMN shares. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $167.70.

Illumina Stock Down 1.5 %

Shares of ILMN stock traded down $1.82 during trading hours on Thursday, hitting $121.05. 962,067 shares of the company were exchanged, compared to its average volume of 1,729,586. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a one year low of $89.00 and a one year high of $217.60. The business’s 50-day simple moving average is $132.44 and its two-hundred day simple moving average is $127.54. The stock has a market capitalization of $19.28 billion, a price-to-earnings ratio of -16.74 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.14 earnings per share. Illumina’s revenue was up 3.6% on a year-over-year basis. Sell-side analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.